Viracta Therapeutics, Inc. (NASDAQ:VIRX) Short Interest Update

Viracta Therapeutics, Inc. (NASDAQ:VIRX) was the recipient of a significant decrease in short interest in December. As of December 31st, there was short interest totalling 609,900 shares, a decrease of 79.7% from the December 15th total of 3,000,000 shares. Approximately 2.2% of the shares of the company are short sold. Based on an average trading volume of 2,690,000 shares, the short-interest ratio is currently 0.2 days.

Viracta Therapeutics Stock Down 6.1 %

Shares of Viracta Therapeutics stock traded down $0.01 during trading on Monday, hitting $0.17. 757,272 shares of the stock traded hands, compared to its average volume of 3,380,881. The stock has a market cap of $6.94 million, a price-to-earnings ratio of -0.16 and a beta of 0.66. Viracta Therapeutics has a 52 week low of $0.13 and a 52 week high of $1.31. The firm’s fifty day moving average is $0.18 and its 200-day moving average is $0.28.

Analyst Ratings Changes

A number of research analysts have recently commented on VIRX shares. Royal Bank of Canada reduced their price target on shares of Viracta Therapeutics from $4.00 to $2.00 and set an “outperform” rating for the company in a research report on Thursday, November 14th. Rodman & Renshaw reaffirmed a “neutral” rating and issued a $0.25 target price (down from $3.50) on shares of Viracta Therapeutics in a research note on Friday, December 27th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $4.05.

Hedge Funds Weigh In On Viracta Therapeutics

A hedge fund recently bought a new stake in Viracta Therapeutics stock. Stonepine Capital Management LLC bought a new stake in shares of Viracta Therapeutics, Inc. (NASDAQ:VIRX) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 500,000 shares of the company’s stock, valued at approximately $116,000. Stonepine Capital Management LLC owned 1.27% of Viracta Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 31.37% of the company’s stock.

About Viracta Therapeutics

Viracta Therapeutics, Inc, a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir.